HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Heinz-Josef Lenz Selected Research

Ipilimumab

10/2022First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.
11/2019Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer.
10/2018Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Heinz-Josef Lenz Research Topics

Disease

237Neoplasms (Cancer)
05/2024 - 01/2002
206Colorectal Neoplasms (Colorectal Cancer)
03/2024 - 01/2002
32Colonic Neoplasms (Colon Cancer)
09/2023 - 09/2004
24Adenocarcinoma
11/2022 - 08/2004
20Microsatellite Instability
04/2023 - 01/2007
18Neoplasm Metastasis (Metastasis)
05/2023 - 03/2006
18Disease Progression
10/2022 - 09/2004
15Stomach Neoplasms (Stomach Cancer)
09/2022 - 02/2006
13Rectal Neoplasms (Rectal Cancer)
12/2023 - 01/2005
12Breast Neoplasms (Breast Cancer)
04/2024 - 01/2003
11Exanthema (Rash)
10/2020 - 04/2005
10Pancreatic Neoplasms (Pancreatic Cancer)
10/2020 - 01/2003
9Leukemia
03/2024 - 11/2005
9Carcinogenesis
10/2023 - 06/2003
8Hypertension (High Blood Pressure)
01/2023 - 08/2005
7Fatigue
01/2023 - 01/2013
7Hepatocellular Carcinoma (Hepatoma)
11/2022 - 04/2007
7Ovarian Neoplasms (Ovarian Cancer)
01/2022 - 03/2005
7Neutropenia
02/2019 - 03/2006
7Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
11/2018 - 06/2004
6Inflammation (Inflammations)
01/2024 - 01/2016
6Gastrointestinal Neoplasms (Gastrointestinal Cancer)
01/2023 - 02/2004
6Carcinoma (Carcinomatosis)
02/2021 - 03/2005
6Esophageal Neoplasms (Esophageal Cancer)
01/2018 - 01/2010
4Circulating Neoplastic Cells
09/2021 - 03/2012
4Neuroendocrine Tumors (Neuroendocrine Tumor)
12/2020 - 07/2008
4Diarrhea
12/2017 - 05/2008
3Cholangiocarcinoma
09/2022 - 12/2011
3Urinary Bladder Neoplasms (Bladder Cancer)
09/2022 - 10/2013
3Nausea
10/2020 - 08/2014
3Vomiting
10/2020 - 08/2004
3Lung Neoplasms (Lung Cancer)
07/2020 - 06/2004

Drug/Important Bio-Agent (IBA)

57Bevacizumab (Avastin)FDA Link
03/2024 - 09/2004
55Biomarkers (Surrogate Marker)IBA
05/2024 - 08/2005
54Cetuximab (Erbitux)FDA Link
03/2024 - 09/2004
46Oxaliplatin (Eloxatin)FDA LinkGeneric
05/2024 - 06/2002
40Irinotecan (Camptosar)FDA LinkGeneric
03/2024 - 01/2003
37Fluorouracil (Carac)FDA LinkGeneric
12/2023 - 01/2002
35Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2022 - 09/2004
33ErbB Receptors (EGF Receptor)IBA
01/2023 - 01/2005
26DNA (Deoxyribonucleic Acid)IBA
03/2024 - 01/2003
21Monoclonal AntibodiesIBA
03/2024 - 04/2005
20Proteins (Proteins, Gene)FDA Link
12/2023 - 01/2004
19Messenger RNA (mRNA)IBA
11/2022 - 01/2002
15Thymidylate SynthaseIBA
01/2019 - 01/2002
14Immune Checkpoint InhibitorsIBA
05/2024 - 01/2017
14GemcitabineFDA Link
10/2020 - 11/2002
14ParaffinIBA
11/2018 - 03/2005
13Leucovorin (Folinic Acid)FDA Link
12/2023 - 01/2003
11Interleukin-8 (Interleukin 8)IBA
04/2015 - 05/2005
10Phosphotransferases (Kinase)IBA
02/2024 - 04/2007
10Capecitabine (Xeloda)FDA Link
01/2022 - 01/2002
10Formaldehyde (Formol)FDA Link
11/2018 - 12/2007
9RNA (Ribonucleic Acid)IBA
03/2024 - 12/2008
9LigandsIBA
01/2024 - 06/2007
9regorafenibIBA
05/2021 - 01/2013
9Panitumumab (Vectibix)FDA Link
01/2019 - 01/2006
8PlatinumIBA
01/2022 - 11/2002
8Epidermal Growth Factor (EGF)IBA
05/2020 - 07/2006
8AntibodiesIBA
01/2020 - 08/2011
6NivolumabIBA
03/2024 - 01/2017
6trifluridine tipiracil drug combinationIBA
02/2019 - 05/2015
6Cyclooxygenase 2 (Cyclooxygenase-2)IBA
12/2018 - 05/2005
5Cell-Free Nucleic AcidsIBA
09/2022 - 08/2015
5B7-H1 AntigenIBA
01/2022 - 04/2015
5VorinostatFDA Link
01/2021 - 07/2009
5Histone Deacetylase InhibitorsIBA
01/2021 - 07/2009
5Immunoglobulin G (IgG)IBA
02/2018 - 01/2006
5Lapatinib (GW572016)FDA Link
01/2016 - 01/2009
5EnzymesIBA
11/2014 - 01/2002
5Cisplatin (Platino)FDA LinkGeneric
05/2012 - 01/2003
4Calcibiotic Root Canal SealerIBA
02/2024 - 01/2019
4Programmed Cell Death 1 ReceptorIBA
01/2024 - 04/2015
4Histones (Histone)IBA
01/2023 - 08/2013
4Trastuzumab (Herceptin)FDA Link
01/2023 - 05/2007
4Poly(ADP-ribose) Polymerase InhibitorsIBA
01/2022 - 03/2012
4Angiogenesis InhibitorsIBA
01/2020 - 12/2004
4Sorafenib (BAY 43-9006)FDA Link
01/2018 - 08/2005
4Thymidine PhosphorylaseIBA
11/2017 - 01/2002
4Erlotinib Hydrochloride (CP 358,774)FDA Link
06/2015 - 04/2005
4Codon (Codons)IBA
03/2015 - 03/2003
4Estrogen ReceptorsIBA
10/2013 - 01/2011
4PanobinostatIBA
08/2013 - 07/2009
4Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
03/2013 - 08/2005
4BilirubinIBA
08/2012 - 08/2004
4Bortezomib (Velcade)FDA Link
12/2011 - 01/2004
3Neurotransmitter Agents (Neurotransmitter)IBA
09/2023 - 10/2022
3Circulating Tumor DNAIBA
01/2023 - 01/2020
3IpilimumabIBA
10/2022 - 10/2018
3MicroRNAs (MicroRNA)IBA
06/2020 - 09/2014
3Antineoplastic Agents (Antineoplastics)IBA
01/2020 - 01/2003

Therapy/Procedure

107Drug Therapy (Chemotherapy)
03/2024 - 06/2002
101Therapeutics
05/2024 - 10/2003
15Immunotherapy
01/2024 - 01/2016
7Adjuvant Chemotherapy
11/2020 - 01/2003
5Neoadjuvant Therapy
12/2023 - 01/2005
5Lasers (Laser)
04/2009 - 09/2006
4Combination Drug Therapy (Combination Chemotherapy)
12/2020 - 06/2002
4Biological Therapy
12/2019 - 04/2014
4Radiotherapy
02/2016 - 05/2012